34% of Professional Investors Are Interested in Building Biodiversity-themed Financial Products
19.7.2023 11:00:00 EEST | Business Wire | Press release
Global sustainability tech platform, Clarity AI and impact data and analytics provider GIST Impact recently convened over 180 asset managers, wealth managers, and asset owners for a highly engaging virtual event, to discuss the crucial role of biodiversity in the investment landscape.
The virtual event shed light on the substantial commitment of financial institutions to incorporate biodiversity into their decision-making processes. Notably, the 140 signatories of the Finance for Biodiversity initiative collectively manage an impressive $20 trillion in assets. This signals a noteworthy upcoming shift within the industry; currently investments focused on biodiversity represent only $2.9 billion compared to the over $40 trillion associated with the broader ESG market.
When surveyed during the event, more than two-thirds of participants highlighted "building biodiversity-themed financial products," and "setting company strategy and targets using the TNFD framework" as the most important priorities on biodiversity, with each answer receiving 34% and 33% of the vote respectively.
Angel Agudo, Board Director and SVP of Product at Clarity AI, expressed enthusiasm about the distribution of the 140 signatories among countries in the Finance for Biodiversity initiative. Mr. Agudo highlighted France as a leading nation where this initiative has materialized into specific regulations. However, he also emphasized the positive global representation, including the Netherlands, the UK, the USA, and other regions. Agudo anticipates the continuous growth of global representation, with more individuals joining the cause from diverse geographies.
Mr. Agudo noted, “I believe that science is great for all of us, not only for the economy but also for our survival. The good thing is that we are seeing very positive traction in the market recognizing the importance of biodiversity. We are acknowledging that it deserves attention and creating products that address the challenge, identifying the right companies and policies to improve their impact on this dimension.”
Pavan Sukhdev, the CEO and founder of GIST Impact and former president of WWF International, emphasized the importance of credible biodiversity impact data and how GIST Impact and Clarity AI’s work is meeting that need, revealing that together they are enabling access to extensive data on over 13,000 of companies. This data empowers participants to assess and compare nature-related impacts and dependencies within their specific sectors.
Mr. Sukhdev provided an example for those interested in creating biodiversity-themed products, suggesting that understanding the Potentially Disappearing Fraction (PDF) of species and its changes over time can serve as a valuable initial indicator for creating an index or deciding what to incorporate into an ETF.
On data availability and estimation capabilities, Mr. Sukhdev said, “While companies may not always disclose all the necessary information regarding their emissions, waste, and pollution, our approach allows us to provide estimates and calculate the Potentially Disappearing Fraction (PDF) of species as a measure of biodiversity impact. With this, we can compare impacts, for example, between similar chemical factories in France and across Europe.”
On AI, Mr. Agudo added, “Ensuring the quality of data is crucial, and technology can help with systematic data validation. Using reliability algorithms and models, data points can be challenged and put into context across time, industry benchmarks, and other indicators. Outliers can be easily identified, and engagement with companies can help improve their disclosure and data accuracy. For users managing portfolios composed of multiple companies or funds, technology facilitates data aggregation from asset-level data to portfolio-level data. This automation enables users to manage portfolios effectively and make informed decisions about including or excluding companies based on their impact and risk profiles related to biodiversity.”
Clarity AI recognizes the ongoing efforts and acknowledges the importance of measuring and disclosing corporate impacts on biodiversity. The company remains dedicated to providing tools, data, and methodologies to empower investors to incorporate biodiversity considerations in a meaningful and impactful manner into portfolios, goal-setting and reporting.
About Clarity AI:
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. Clarity AI’s capabilities are an essential tool for end-to-end sustainability analysis related to investing, corporate research, benchmarking, consumer ecommerce, and regulatory reporting. As of June 2023, Clarity AI’s platform analyzes more than 70,000 companies, 420,000 funds, 201 countries, and 199 local governments, which represents more breadth than any other player in the market. One way Clarity AI delivers on its mission to bring societal impact to markets is by ensuring its capabilities are delivered directly into clients' workflows through integrations with partners like BlackRock - Aladdin, Refinitiv an LSEG business, BNP Manaos, CACEIS, and Simcorp. Additionally, Clarity AI's sustainability insights reach more than 150 million consumers across more than 400,000 merchants on the Klarna platform. Clarity AI has offices in North America, Europe, and the Middle East, and its client network manages tens of trillions in assets and includes companies like Invesco, Nordea, BlackRock, Santander, Wellington, and BNP Paribas.
About GIST Impact
GIST Impact is a leading impact data and analytics provider that has been measuring and quantifying corporate impacts for more than 15 years.
GIST Impact’s historic and deep expertise in the economics of ecosystems and biodiversity (TEEB) enriches its clients' knowledge of their impacts and dependencies on nature.
With a team of 100+ scientists, engineers, data scientists and ecological and environmental economists, GIST Impact codifies this experience within its market-leading impact platforms and datasets, covering 12,800+ companies with geographically precise, time-series data.
GIST Impact works with pioneering companies across all sectors and with investors representing over $8 trillion in assets under management.
GIST Impact also partners with some of the world's largest ESG data providers, business networks, and fintech platforms to enable impact measurement across global markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719446459/en/
Contact information
Clarity AI Media Contact
Edelman Smithfield
clarityai@edelmansmithfield.com
GIST Impact Media Contact
Alexandra Downs
alexandra@gistimpact.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 09:00:00 EEST | Press release
Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Through Reporting (STR) vision and leveraging the combined capabilities of the transaction to deliver more resilient, transparen
AB InBev Reports First Quarter 2026 Results5.5.2026 08:02:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer
Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release
Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent
Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release
CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
